皮肤黑色素瘤流行病学及防治研究进展

Abstract
Figure/Table
References (41)
Related Citation (15)

Download: PDF (551 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Melanoma is one of the deadliest types of skin cancer. Over the past two decades, the prevalence rate of melanoma of skin was on the rise. Melanoma of the skin as a clinical problem has become a serious public health issue and has drawn much attention. This review discusses the epidemiology of melanoma of the skin, as well as the treatment and prevention of the condition. The purpose of this review is to present an introduction to the subject, and to be assisted in better understanding for clinicians.

Key words： Skin cancer Melanoma Epidemiology Prevention Diagnosis Therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Qianli ZHANG Wenjun WANG Hui JIANG Hua▲

Cite this article:

LIN Qianli ZHANG Wenjun WANG Hui JIANG Hua▲. Research progress on epidemiology, treatment and prevention of malignant melanoma of skin[J]. 中国医药导报, 2019, 16(3): 28-32.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I3/28

[1] NIH. National Cancer Institute，Skin Cancer（Including Melanoma）-Patient Version [EB/OL]. 2017. https：//www.cancer.gov/types/skin.
[2] CDC. Centers for Disease Control and Prevention，Skin Cancer [EB/OL]. Updated 2017. https：//www.cdc.gov/cancer/skin/.
[3] NIH. U.S. National Library of Medicine，MedlinePlus，Skin Cancer [EB/OL]. Updated 2018. https：//medlineplus.gov/skincancer.html.
[4] CDC. Centers for Disease Cotrol and Prevention，Cancer Prevention and Control，State of the Science on Melanoma Prevention and Screening [EB/OL]. https：//www.cdc.gov/cancer/dcpc/research/articles/melanoma_risehtm.
[5] Veierød MB. Melanoma incidence on the rise again [J]. Tidsskr Nor Laegeforen，2015，135（5）：450-452.
[6] Ossio R，Roldan-Marin R，Martinez-Said H，et al. Melanoma：a global perspective [J]. Nat Rev Cancer，2017，17（7）：393-394.
[7] NIH. National Cancer Institute，Surveillance，Epidemiology，and End Results Program，Cancer Stat Facts：Melanoma of the Skin [EB/OL]. 2017. https：//seer.cancer.gov/statfacts/html/melanhtml.
[8] Ward-Peterson M，Acuña JM，Alkhalifah MK，et al. Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades：A Secondary Analysis of SEER Data [J]. Medicine（Baltimore），2016，95（17）：e3315.
[9] Dawes SM，Tsai S，Gittleman H，et al. Racial disparities in melanoma survival [J]. J Am Acad Dermatol，2016，75（5）：983-991.
[10] Gandini S，Autier P，Boniol M. Reviews on sun exposure and artificial light and melanoma [J]. Prog Biophys Mol Biol，2011，107（3）：362-366.
[11] Hohmann CB，Bonamigo RR，Segatto MM，et al. Could a specific dietary intake be a risk factor for cutaneous melanoma？[J]. Cutis，2016，97（6）：421-425.
[12] Czarnecki D. The incidence of melanoma is increasing in the susceptible young Australian population [J]. Acta Derm Venereol，2014，94（5）：539-541.
[13] Gandini S，Sera F，Cattaruzza MS，et al. Meta-analysis of risk factors for cutaneous melanoma：I. Common and atypical naevi [J]. Eur J Cancer，2005，41（1）：28-44.
[14] Patient Perspectives：Moles and melanoma in children and teens [J]. Pediatr Dermatol，2015，32（6）：e320-e321.
[15] Sinnamon AJ，Neuwirth MG，Yalamanchi P，et al. Association Between Patient Age and Lymph Node Positivity in Thin Melanoma [J]. JAMA Dermatol，2017，153（9）：866-873.
[16] Wadt KA，Drzewiecki KT，Gerdes AM. High accuracy of family history of melanoma in Danish melanoma cases [J]. Fam Cancer，2015，14（4）：609-613.
[17] Margolin K. Introduction to the role of the immune system in melanoma [J]. Hematol Oncol Clin North Am，2014，28（3）：537-558.
[18] Ide M，Koba S，Sueoka-Aragane N，et al. Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients [J]. Pathol Oncol Res，2017，23（1）：181-188.
[19] Franzoni A，Markova-Car E，Devic-Pavlic S，et al. A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma [J]. Exp Biol Med（Maywood），2017，242（15）：1553-1558.
[20] Tiffen J，Wilson S，Gallagher SJ，et al. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma [J]. Neoplasia，2016，18（2）：121-132.
[21] Situm M，Buljan M，Kolic M，et al. Melanoma--clinical，dermatoscopical，and histopathological morphological characteristics [J]. Acta Dermatovenerol Croat，2014，22（1）：1-12.
[22] American Academy of Dermatology Ad Hoc Task Force for the ABCDEs of Melanoma，Tsao H，Olazagasti JM，et al. Early detection of melanoma：reviewing the ABCDEs [J]. J Am Acad Dermatol，2015，72（4）：717-723.
[23] Rastrelli M，Tropea S，Rossi CR，et al. Melanoma：epidemiology，risk factors，pathogenesis，diagnosis and classification [J]. In Vivo，2014，28（6）：1005-1011.
[24] Gershenwald JE，Scolyer RA，Hess KR，et al. Melanoma staging：Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual [J]. CA Cancer J Clin，2017，67（6）：472-492.
[25] NIH. National Cancer Institute，Melanoma Treatment（PDQ?誖）-Patient Version [EB/OL]. 2017. https：//www.cancer.gov/types/skin/patient/melanoma-treatment-pdq# section/_135.
[26] Raigani S，Cohen S，Boland GM. The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy [J]. Curr Oncol Rep，2017，19（3）：17.
[27] Di Martino M，Garcia Sanz I，Mora-Guzman I，et al. Surgery in late melanoma adrenal metastasis [J]. BMJ Case Rep，2017，2017. pii：bcr2016218681.
[28] Stigall LE，Brodland DG，Zitelli JA. The use of Mohs micrographic surgery（MMS）for melanoma in situ（MIS） of the trunk and proximal extremities [J]. J Am Acad Dermatol，2016，75（5）：1015-1021.
[29] NIH. National Cancer Institute，Drugs Approved for Mel-anoma [EB/OL]. 2017. https：//www.cancer.gov/about-cancer/treatment/drugs/melanoma.
[30] DeVita VT，Lawrence TS，Rosenberg SA. DeVita，Hellman，and Rosenberg′s Cancer：Principles & Practice of Oncology [M]. Wolters Kluwer Health/Lippincott Williams & Wilkins，2011.
[31] Shi W. Role for radiation therapy in melanoma [J]. Surg Oncol Clin N Am，2015，24（2）：323-335.
[32] Yan WL，Shen KY，Tien CY，et al. Recent progress in GM-CSF-based cancer immunotherapy [J]. Immunotherapy，2017，9（4）：347-360.
[33] O'Reilly A，Larkin J. Checkpoint inhibitors in advanced melanoma：effect on the field of immunotherapy [J]. Expert Rev Anticancer Ther，2017，17（7）：647-655.
[34] Valpione S，Campana LG. Immunotherapy for advanced melanoma：future directions [J]. Immunotherapy，2016，8（2）：199-209.
[35] Pyo JS，Kang G. Immunotherapy in advanced melanoma：a network meta-analysis [J]. Immunotherapy，2017，9（6）：471-479.
[36] Johnson DB，Pollack MH，Sosman JA. Emerging targeted therapies for melanoma [J]. Expert Opin Emerg Drugs，2016，21（2）：195-207.
[37] Amann VC，Ramelyte E，Thurneysen S，et al. Developments in targeted therapy in melanoma [J]. Eur J Surg Oncol，2017，43（3）：581-593.
[38] Ott PA，Fritsch EF，Wu CJ，et al. Vaccines and melanoma [J]. Hematol Oncol Clin North Am，2014，28（3）：559-569.
[39] NIH. National Cancer Institute，Phase IIB TL+YCWP+DC in Melanoma [EB/OL]. https：//www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?q=Vaccines+for+melanoma&loc=0&rl=1&id=NCI-2014-02585&pn=1&ni=10，Clinicaltrials. gov ID NCT02301611.
[40] NIH. National Cancer Institute，Cobimetinib（Targeted Therapy）Plus Atezolizumab（Immunotherapy）in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma [EB/OL]. https：//www.cancer. gov/about-cancer/treatment/clinical-trials/search/v?q=Targeted+therapy+for+melanoma&loc=0&rl=1&id=NCI-2017-01067&pn=1&ni=10，Clinicaltrials. gov ID NCT03178851.
[41] NIH. National Cancer Institute，PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma [EB/OL]. https：//www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?q=Regional+chemotherapy+for+melanoma&loc=0&rl=1&id=NCI-2015-00568&pn=1&ni=10，Clinicaltrials. gov ID NCT02288897.